CXCL9 and neoplasm: Peak expression was observed at the 20 μg free CDN dose while the higher dose of 100 μg that was required for distal non-injected tumor control (Fig. 2d) and led to immune ablation (Fig. 2e) resulted in decreased CXCL9 production (Fig. 5f).